Compass Therapeutics (NASDAQ:CMPX) PT Raised to $9.00

Compass Therapeutics (NASDAQ:CMPXGet Rating) had its price target boosted by equities researchers at LADENBURG THALM/SH SH to $9.00 in a research note issued to investors on Wednesday, Stock Target Advisor reports. LADENBURG THALM/SH SH’s target price would indicate a potential upside of 100.89% from the stock’s previous close.

A number of other brokerages have also commented on CMPX. Raymond James raised their price objective on Compass Therapeutics from $5.00 to $8.00 and gave the stock an “outperform” rating in a research report on Thursday, November 10th. HC Wainwright decreased their price objective on Compass Therapeutics from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, November 3rd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $10.29.

Compass Therapeutics Stock Down 0.4 %

NASDAQ:CMPX opened at $4.48 on Wednesday. Compass Therapeutics has a 1-year low of $1.25 and a 1-year high of $4.85. The firm has a market capitalization of $565.34 million and a price-to-earnings ratio of -10.74. The stock has a fifty day simple moving average of $3.16 and a 200 day simple moving average of $2.83.

Insider Activity at Compass Therapeutics

In related news, CEO Thomas J. Schuetz acquired 15,000 shares of the business’s stock in a transaction that occurred on Monday, September 26th. The shares were acquired at an average cost of $2.27 per share, with a total value of $34,050.00. Following the purchase, the chief executive officer now owns 5,421,873 shares of the company’s stock, valued at $12,307,651.71. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Compass Therapeutics news, CEO Thomas J. Schuetz purchased 15,000 shares of the company’s stock in a transaction on Monday, September 26th. The shares were bought at an average cost of $2.27 per share, with a total value of $34,050.00. Following the transaction, the chief executive officer now directly owns 5,421,873 shares in the company, valued at approximately $12,307,651.71. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Orbimed Advisors Llc purchased 402,000 shares of the company’s stock in a transaction on Tuesday, November 8th. The stock was acquired at an average cost of $3.21 per share, for a total transaction of $1,290,420.00. Following the completion of the transaction, the director now owns 15,219,994 shares in the company, valued at $48,856,180.74. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 427,000 shares of company stock valued at $1,347,670. Corporate insiders own 29.80% of the company’s stock.

Institutional Trading of Compass Therapeutics

Institutional investors have recently modified their holdings of the company. Flagship Harbor Advisors LLC acquired a new stake in Compass Therapeutics in the 2nd quarter valued at $37,000. Jane Street Group LLC acquired a new stake in Compass Therapeutics in the 3rd quarter valued at $33,000. Qube Research & Technologies Ltd boosted its stake in Compass Therapeutics by 81.9% in the 1st quarter. Qube Research & Technologies Ltd now owns 52,842 shares of the company’s stock valued at $72,000 after buying an additional 23,789 shares in the last quarter. New Capital Management LP acquired a new stake in Compass Therapeutics in the 2nd quarter valued at $69,000. Finally, Bank of New York Mellon Corp acquired a new stake in Compass Therapeutics in the 3rd quarter valued at $55,000. Institutional investors and hedge funds own 61.11% of the company’s stock.

About Compass Therapeutics

(Get Rating)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137.

Read More

Stock Target Advisor logo

Analyst Recommendations for Compass Therapeutics (NASDAQ:CMPX)

Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.